Therapeutic vaccine improves response rate and extends progression-free survival in patients with metastatic melanoma
Patrick Hwu, MD, Chair of the Department of Melanoma Medical Oncology M. D. Anderson Cancer Center: Therapeutic Vaccine Improves Response Rate and Extends Progression-Free Survival in Patients with Metastatic Melanoma: Preliminary findings from a phase III, multicenter trial show that adding a novel cancer vaccine – called gp100:209-217(210M) peptide – to standard therapy doubles response rates and extends progression-free survival in patients with metastatic melanoma, without causing significant side effects.
Comments on this video Report unsuitable comment
No comments have been made on this video yet, be the first to voice your opinion, use the form on the right.
Add a comment